NEW YORK, April 25 - Biogen has licensed the Rosetta Resolver gene expression analysis system from Rosetta Inpharmatics, the companies said Wednesday.

Biogen will use the Resolver system to manage and analyze its gene expression data, the pharmaceutical company said in a statement. The companies did not disclose financial details of the deal.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.